In vitro effects of imatinib on CD34+ cells of patients with chronic myeloid leukemia in the megakaryocytic crisis phase

  • Authors:
    • Fankai Meng
    • Wen Zeng
    • Lifang Huang
    • Shuang Qin
    • Ningning Miao
    • Hanying Sun
    • Chunrui Li
  • View Affiliations

  • Published online on: January 2, 2014     https://doi.org/10.3892/ol.2014.1780
  • Pages: 791-796
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Imatinib is a tailored drug for the treatment of chronic myeloid leukemia (CML), and has substantial activity and a favorable safety profile when used as a single agent in patients with CML in myeloid blast crisis. The megakaryocytic blast crisis in CML occurs rarely and carries a poor prognosis. The aim of the present study was to investigate the effects of imatinib on cluster of differentiation (CD)34+ cells from patients with CML in the megakaryocytic crisis phase. Bone marrow mononuclear cells (BMNCs) were isolated from patients with CML in the megakaryocytic crisis phase. CD34+ cells were selected from BMNCs by positive immunomagnetic column separation. Imatinib significantly induced G1 arrest, reduced the phosphorylation of cyclin‑dependent kinase 1 and retinoblastoma proteins and inhibited the proliferation of CD34+ cells from patients with CML in the megakaryocytic crisis phase. Annexin V/propidium iodide and caspase‑3 activity showed that imatinib induced apoptosis. Western blot analysis and protein tyrosine kinase activity assays showed that imatinib inhibited BCR‑ABL protein tyrosine kinase activity. The in vitro data thus markedly indicate a potential clinical application of imatinib for patients with CML in the megakaryocytic crisis phase.
View Figures
View References

Related Articles

Journal Cover

2014-March
Volume 7 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Meng F, Zeng W, Huang L, Qin S, Miao N, Sun H and Li C: In vitro effects of imatinib on CD34+ cells of patients with chronic myeloid leukemia in the megakaryocytic crisis phase. Oncol Lett 7: 791-796, 2014
APA
Meng, F., Zeng, W., Huang, L., Qin, S., Miao, N., Sun, H., & Li, C. (2014). In vitro effects of imatinib on CD34+ cells of patients with chronic myeloid leukemia in the megakaryocytic crisis phase. Oncology Letters, 7, 791-796. https://doi.org/10.3892/ol.2014.1780
MLA
Meng, F., Zeng, W., Huang, L., Qin, S., Miao, N., Sun, H., Li, C."In vitro effects of imatinib on CD34+ cells of patients with chronic myeloid leukemia in the megakaryocytic crisis phase". Oncology Letters 7.3 (2014): 791-796.
Chicago
Meng, F., Zeng, W., Huang, L., Qin, S., Miao, N., Sun, H., Li, C."In vitro effects of imatinib on CD34+ cells of patients with chronic myeloid leukemia in the megakaryocytic crisis phase". Oncology Letters 7, no. 3 (2014): 791-796. https://doi.org/10.3892/ol.2014.1780